ClinicalTrials.gg
CompletedNCT06704763Updated May 26, 2026Results posted

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

A Phase 1 interventional study of Orforglipron and Midazolam in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants.

The study will last up to approximately 8 weeks including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and (ECG)
  • Have a level of:

    • at least 11.4 grams per deciliter (g/dL) for individuals assigned female at birth (AFAB), and
    • at least 12.5 g/dL for individuals assigned male at birth (AMAB)
  • Have a body weight equal to or greater than 45 kilograms (kg), and a within the range of 18.5 to 35.0 kilogram per square meter (kg/m²) at screening

Exclusion criteria

Exclusion Criteria:

  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, psychological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting risk when taking orforglipron, midazolam, or quinidine; or interfering with the interpretation of data
  • Have a 12 lead (ECG) abnormality, including known prolongation of /QTc interval, significant bradycardia, significant heart blocks or a history of any risk factors for ventricular arrhythmia, heart failure, hypokalemia or hypomagnesemia, or other factors that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal blood pressure or pulse rate, deemed to be by the investigator
  • Have a history of benign ethnic neutropenia
  • Have a GI disease or disorder, such as relevant esophageal reflux or gall bladder disease, which could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or impacts gastric emptying, for example gastric bypass surgery or pyloric stenosis, except for appendectomy
  • Have a history or presence of pancreatitis, including chronic pancreatitis or idiopathic acute pancreatitis
  • Have known allergies to:

    • quinidine
    • midazolam
    • orforglipron
    • related compounds, or
    • any components of the formulation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Midazolam + Orforglipron + Quinidine

    Participants received: * Day -1: single dose of 0.2 milligram (mg) midazolam. * Day 1: single dose of 1 mg orforglipron. * Days 5 to 6: 200 mg quinidine twice daily (BID). * Day 7: 200 mg quinidine BID plus a single dose of 0.2 mg midazolam. * Day 8: 200 mg quinidine BID plus a single dose of 1 mg orforglipron.

    Drug: Orforglipron · Drug: Midazolam · Drug: Quinidine

Interventions

  • Administered orally

    Also known as: LY3502970

  • DrugMidazolam

    Administered orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron

    PK: AUC0-inf of Orforglipron.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8

  2. PK: Maximum Observed Concentration (Cmax) of Orforglipron

    PK: Cmax of Orforglipron.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8

Secondary outcomes

  1. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam

    PK: AUC0-inf of Midazolam.

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

  2. PK: Maximum Concentration (Cmax) of Midazolam

    PK: Cmax of Midazolam.

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam

    PK: AUC0-inf of 1-Hydroxymidazolam (metabolite of Midazolam).

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

  4. PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam

    PK: Cmax of 1-Hydroxymidazolam (metabolite of Midazolam).

    Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7

07

Results

Posted May 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneMidazolam + Orforglipron + Quinidine
Started27
Received at least one dose of study drug27
Completed27
Not completed0

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron

PK: AUC0-inf of Orforglipron.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8
Reported as:
Geometric mean · nanogram*hour per milliliter
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron
nanogram*hour per milliliterMidazolam + Orforglipron + Quinidine
Day 189.9 ± 30.4
Day 879.1 ± 30.2
PrimaryPK: Maximum Observed Concentration (Cmax) of Orforglipron

PK: Cmax of Orforglipron.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96 hours post orforglipron dose on days 1, 8
Reported as:
Geometric mean · nanogram per milliliter
PK: Maximum Observed Concentration (Cmax) of Orforglipron
nanogram per milliliterMidazolam + Orforglipron + Quinidine
Day 14.11 ± 32.2
Day 83.06 ± 39.6
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam

PK: AUC0-inf of Midazolam.

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
Reported as:
Geometric mean · nanogram*hour per milliliter
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam
nanogram*hour per milliliterMidazolam + Orforglipron + Quinidine
Day -12.06 ± 41.7
Day 72.73 ± 42.1
SecondaryPK: Maximum Concentration (Cmax) of Midazolam

PK: Cmax of Midazolam.

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
Reported as:
Geometric mean · nanogram per milliliter
PK: Maximum Concentration (Cmax) of Midazolam
nanogram per milliliterMidazolam + Orforglipron + Quinidine
Day -10.725 ± 35.2
Day 70.999 ± 49.2
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam

PK: AUC0-inf of 1-Hydroxymidazolam (metabolite of Midazolam).

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
Reported as:
Geometric mean · nanogram*hour per milliliter
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of 1-Hydroxymidazolam
nanogram*hour per milliliterMidazolam + Orforglipron + Quinidine
Day -10.676 ± 39.2
Day 70.999 ± 38
SecondaryPK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam

PK: Cmax of 1-Hydroxymidazolam (metabolite of Midazolam).

Time frame:
Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post midazolam dose on days -1, 7
Reported as:
Geometric mean · nanogram per milliliter
PK: Maximum Concentration (Cmax) of 1-Hydroxymidazolam
nanogram per milliliterMidazolam + Orforglipron + Quinidine
Day -10.224 ± 39.6
Day 70.343 ± 50.5

Adverse events

Collected over Day -1 through the end of study (Up To 21 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.2 mg Midazolam (Day -1)0/27 (0%)0/27 (0%)4/27 (14.8%)
1 mg Orforglipron (Days 1 to 4)0/27 (0%)0/27 (0%)7/27 (25.9%)
200 mg Quinidine BID (Days 5 to 6)0/27 (0%)0/27 (0%)6/27 (22.2%)
200 mg Quinidine BID + 0.2mg Midazolam (Day 7)0/27 (0%)0/27 (0%)1/27 (3.7%)
200mg Quinidine BID + 1mg Orforglipron (Day 8 to End of Study)0/27 (0%)0/27 (0%)7/27 (25.9%)
Most frequent other events
Showing 10 of 28
Most frequent other events
Event0.2 mg Midazolam (Day -1)1 mg Orforglipron (Days 1 to 4)200 mg Quinidine BID (Days 5 to 6)200 mg Quinidine BID + 0.2mg Midazolam (Day 7)200mg Quinidine BID + 1mg Orforglipron (Day 8 to End of Study)
NauseaGastrointestinal disorders1/273/270/270/271/27
Abdominal painGastrointestinal disorders0/270/272/270/271/27
HeadacheNervous system disorders2/270/270/270/270/27
PalpitationsCardiac disorders0/270/270/271/271/27
Dry eyeEye disorders0/271/270/270/270/27
Vision blurredEye disorders0/270/271/270/270/27
Abdominal distensionGastrointestinal disorders0/271/270/270/271/27
DiarrhoeaGastrointestinal disorders0/270/271/270/271/27
FlatulenceGastrointestinal disorders0/271/270/270/270/27
Rectal tenesmusGastrointestinal disorders0/271/270/270/270/27

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Midazolam + Orforglipron + Quinidine
Mean35.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Midazolam + Orforglipron + Quinidine
Female13
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Midazolam + Orforglipron + Quinidine
Hispanic or Latino4
Not Hispanic or Latino23
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Midazolam + Orforglipron + Quinidine
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White22
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Midazolam + Orforglipron + Quinidine
United States27
08

Study locations

1 site
  • ICON
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Feb 2025, 1 month.

Results were first posted in May 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2024
First posted
Nov 26, 2024
StartActual
Dec 6, 2024
Primary completionActual
Feb 5, 2025
CompletionActual
Feb 5, 2025
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06704763
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 6, 2024
Primary completion
Feb 5, 2025
Completion
Feb 5, 2025
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Contact Lilly at 1-800-LillyRx (1-800-545-5979)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion